¸²ÇÁÁ¾ Ä¡·áÀÇ ´ë°¡, ±¹³» īƼ¼¼Æ÷Ä¡·á ¼±±¸ÀÚ
±è¼®Áø ±³¼ö´Â ¸²ÇÁÁ¾ Ä¡·áÀÇ ´ë°¡ÀÌÀÚ ´ëÇÑÇ÷¾×ÇÐȸ ÀÌ»çÀåÀ» ¸Ã°í ÀÖ´Â ±¹³» Ç÷¾×ÇÐ ºÐ¾ßÀÇ ±ÇÀ§ÀÚÀÌ´Ù. ±è¼®Áø ±³¼ö´Â »ï¼º¼¿ïº´¿øÀÌ 2021³â ±¹³» ÃÖÃʷΠīƼ(CAR T)¼¼Æ÷Ä¡·á¼¾ÅÍ °³¼Ò¸¦ ÁÖµµÇÏ´Â µî Çõ½ÅÀûÀÎ Ä¡·á µµÀÔ¿¡ ¾ÕÀå¼¹´Ù. ƯÈ÷ ¸²ÇÁÁ¾ Ä¡·á¿¡¼ »õ ÀÌÁ¤Ç¥¸¦ Á¦½ÃÇÏ´Â ¿¬±¸ÀÚ·Î À¯¸íÇÏ´Ù. 2025³â Ç÷¾×ÇÐ ºÐ¾ß ÃÖ°í ±ÇÀ§ ÇмúÁöÀÎ 'ºí·¯µå(Blood)'¿¡ Ä¡·á°¡ ¾î·Á¿î Àç¹ß¡¤ºÒÀÀ¼º ¸²ÇÁÀý ¿Ü NK/T ¼¼Æ÷ ¸²ÇÁÁ¾(ENKTL)¿¡ ´ëÇØ ºÎÀÛ¿ëÀ» ÁÙÀÌ¸é¼ »ýÁ¸ ±â°£À» ´Ã¸®´Â »õ·Î¿î Ä¡·á¹ýÀ» Á¦½ÃÇÏ´Â ¿¬±¸¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ³Ä¡¼º ¸²ÇÁÁ¾ ±Øº¹À» ¼±µµÇÏ´Â Àü¹®°¡ÀÌ´Ù.
| Á¦ ¸ñ | Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | Blood |
| Á¦ ¸ñ | Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | Annals of Laboratory Medicine |
| Á¦ ¸ñ | CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Blood |
| Á¦ ¸ñ | Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Annals of Laboratory Medicine |
| Á¦ ¸ñ | The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Blood |
| Á¦ ¸ñ | Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | Journal of Oncology |
| Á¦ ¸ñ | Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | Bone Marrow Transplantation |

»ï¼º¼¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.
¼¿ïƯº°½Ã °³²±¸ ÀÏ¿ø·Î 81